News

Childhood Cancer International Day

In France, childhood cancer affects 1 child in 500. It is the second commonest cause of mortality in those under 15 years of age. The number of patients cured continues to rise and today, 80% are cured of their cancer. At Gustave Roussy, all our professional staff work together every day to make the Child and Adolescent Cancer Department an innovative unit in research and care.

Published on

Changed on

In France, childhood cancer affects 1 child in 500. It is the second commonest cause of mortality in those under 15 years of age. The number of patients cured continues to rise and today, 80% are cured of their cancer. At Gustave Roussy, all our professional staff work together every day to make the Child and Adolescent Cancer Department an innovative unit in research and care.

In 1950, Gustave Roussy created the first Paediatric Cancer Unit in France which is the origin of:

  • innovative treatments which today are worldwide treatment recommendations;
  • research studies to reduce sequellae due to the treatment and the illness;
  • early trials on new medicines;
  • a law to encourage the pharmaceutical industry to draw to a close the use of medicines for the treatment of children which are effective in adults.

Overseen by Dr Dominique Valteau-Couanet, this department manages all types of paediatric cancer: neuroblastomas, cerebral tumours, bone and soft tissue tumours, lymphomas, stem cell tumours and rare tumours. Each department physician is an expert at the National, European and International level.  

Special attention focuses on:

  • Appropriate treatment and access to new treatments
  • The quality of care within and outside the hospital environment
  • The readaptation to life after the illness
  • Long term survival.

In order to attain a better overall management, innovative and centred on the needs of young patients, the children and adolescent cancer department of Gustave Roussy has benefited from a thorough architectural restructuring. These new premises were inaugurated in December 2014. 

 

Last news

  • Two photon-counting CT scanners now equip Gustave Roussy's imaging department

    Since September 2026, Gustave Roussy's Department of Medical Imaging has been equipped with a second photon-counting CT scanner, delivering higher image resolution while reducing the doses of X-rays and contrast agent administered to patients. This technology recently enabled the Institute to perform an iodine-free pulmonary CT angiogram, a world first.

    Photographie du scanner à comptage photonique
  • Prevention and screening: getting ahead of lung cancer

    To mark Thoracic Cancer Awareness Month and Tobacco-Free Month, two campaigns focusing on lung cancer, Gustave Roussy highlights its initiatives to advance prevention and screening among people at increased risk. Since its creation in 2021, the Institute’s Interception Lung programme has welcomed more than 900 participants, supporting them to stop smoking and offering personalised screening for the disease.

    Photographie : patient effectuant un scanner thoracique et équipes soignantes
  • Gustave Roussy Meets His Audience

    As part of its awareness-raising and fundraising efforts, Gustave Roussy is currently conducting a door-to-door outreach campaign in several towns in Val-de-Marne (Fresnes, Vitry-sur-Seine, Nogent-sur-Marne, Bry-sur-Marne, Le Kremlin-Bicêtre) from Monday through Saturday, 1:30 p.m. to 8:00 p.m.

    Deux personnes en charge de la collecte porte-à-porte
  • Mens November: Take care of your jewelry its precious!

    November is the month dedicated to raising awareness and promoting prevention of male cancers, which include prostate, testicular, and penile cancers. The goal is to raise public awareness of these diseases—which account for approximately 63,000 new cases in France each year—and to encourage men to perform testicular self-exams, a simple step that can help detect a lump, the nature of which must then be determined through further medical examinations. Gustave Roussy has extensive expertise in the treatment of male cancers, particularly through its Genitourinary Oncology Committee, which is deeply involved in research on these diseases. 

    Visuel fixe campagne novembre masculin